Omeprazole (and derivatives: Esomeprazole, Pantoprazole)

Mechanism

💊 Representative Drugs

• Omeprazole (Omeprazole Normon, Losec)
• Esomeprazole (Nexium, Esomeprazole Sandoz)
• Pantoprazole (Pantecta, Pantoprazole Alter)

🧪 Class Properties

• Class: Proton pump inhibitors (H⁺/K⁺-ATPase).
• Nature: Lipophilic prodrugs of weakly basic character (pKa ≈ 4.0).
• Target: Covalent bonding by disulfide bridge with specific cysteines of the α subunit of the pump.

Mechanism of action

At neutral pH (≈ 7.4), PPIs are non-ionized, highly lipophilic, and easily cross cell membranes. After systemic absorption and capillary distribution, they reach the active secretory canaliculi of the parietal cell via the basolateral route. In this subcellular compartment, characterized by an extremely acidic pH (< 1.0), PPIs undergo rapid double protonation according to the Henderson-Hasselbalch equation:

The protonated (hydrophilic) form is trapped by a pH gradient in the canaliculus ("ionic trapping"). There it undergoes a spontaneous intramolecular chemical rearrangement that transforms it into an active intermediate: a positively charged tetracyclic sulfenamide. This sulfenamide reacts covalently with the sulfhydryl groups of the cysteine residues (mainly Cys₈₁₃ in the case of omeprazole) exposed in the luminal domain of the H⁺/K⁺-ATPase enzyme, blocking its catalytic activity irreversibly.

Cellular Mechanism and Irreversibility

Since the binding is covalent and irreversible, gastric acid secretion is inhibited until new molecules of the H⁺/K⁺-ATPase enzyme are synthesized and inserted into the canalicular membrane. The clearance half-life of the human proton pump ranges from 30 to 48 hours. For this reason, although the plasma half-life of PPIs is short (~1-2 hours), their duration of therapeutic action is prolonged for more than 24 hours.

Pharmacokinetics

Pharmacokinetics

Indicators and dose

Approved and Off-label indications

• Gastroesophageal reflux disease (GERD): Healing of erosive esophagitis and symptomatic maintenance treatment.
• Peptic ulcer: Treatment of active gastric and duodenal ulcers; prevention of ulcers associated with the consumption of NSAIDs in high-risk patients.
• Eradication of Helicobacter pylori: In combination with double or triple antibiotic regimens (clarithromycin, amoxicillin, metronidazole, bismuth). The PPI raises gastric pH (> 5.5), allowing antibiotics to retain their chemical stability and reach effective bactericidal concentrations.
• Pathological hypersecretion syndromes: Zollinger-Ellison syndrome.
• Off-label use: Systematic prophylaxis of digestive bleeding due to stress in patients in intensive care units without clear risk factors (practice advised against by clinical guidelines due to the risk of pneumonia and sepsis).

Dosage and Clinical Adjustment

Adults:

• Symptomatic duodenal ulcer / GERD: 20 mg orally once a day in the morning, 30-60 minutes before breakfast.
• Severe erosive esophagitis / Gastric ulcer due to NSAIDs: 20 mg to 40 mg orally daily for 4 to 8 weeks.
• H. pylori eradication: 20 mg orally every 12 hours in combination with corresponding antibiotic therapy for 10-14 days.
• Active upper gastrointestinal bleeding (IV infusion): Initial bolus of 80 mg intravenously over 30 minutes, followed by a continuous infusion of 8 mg/hour for 72 hours (usually with esomeprazole or pantoprazole).

Pediatrics: Indicated from 12 months of age for GERD and erosive esophagitis. Adjustment for body weight: 10 kg - 20 kg: 10 mg/day; >20 kg: 20 mg/day.

Adjustment in Renal Failure: No dose adjustment is required in patients with renal failure of any degree.

Adjustment in Liver Failure: In patients with decompensated liver cirrhosis or Child-Pugh B/C, drug clearance is markedly decreased and the half-life may be prolonged up to 3-4 hours. A maximum daily dose of 20 mg (omeprazole) or 20 mg every 48 hours in cases of severe dysfunction is recommended.

Security

Contraindications

• Absolute: Known hypersensitivity to omeprazole, substituted benzimidazoles or any component of the formula. Coadministration with rilpivirine or atazanavir (the increase in gastric pH critically compromises its solubility and bioavailability).
• Relative: Severe hepatic impairment (Child-Pugh C) requires close monitoring and reduction of the maximum daily dose. Suspected gastric malignancy (PPIs relieve symptoms and may mask or hinder the diagnosis of gastric adenocarcinoma).

Adverse effects (ADRs)

Drug interactions

• Interactions due to gastric pH: Drastic reduction in the absorption of azole antifungals (ketoconazole, itraconazole), ampicillin esters and iron salts. Increased absorption of digoxin (risk of toxicity due to reduced acid degradation).
• Interaction with Clopidogrel: Omeprazole and esomeprazole are moderate to potent inhibitors of the liver enzyme CYP2C19. Clopidogrel is a prodrug that requires two-stage metabolic activation, in which CYP2C19 plays a limiting role. Coadministration decreases the concentration of the active metabolite of clopidogrel and significantly reduces its antiplatelet effect. Safe alternative: Use pantoprazole, which has a lower metabolic affinity for CYP2C19.
• Drugs with a narrow therapeutic range: Inhibition of hepatic clearance of warfarin, phenytoin and diazepam (requires monitoring of INR and serum levels).

Pregnancy and Breastfeeding Category

Pregnancy: FDA Category C (previous). Although large observational studies and epidemiological meta-analyses have not demonstrated significant teratogenic effects of omeprazole in humans, its use should be reserved for clear indications where the benefits outweigh the potential risks. Esomeprazole and pantoprazole are preferred under strict obstetric supervision.

Breastfeeding: Compatible. PPIs are excreted in breast milk in minimal quantities (RID < 1%). Additionally, the remaining drug is acid labile and is rapidly destroyed in the acidic gastric environment of the infant, so the actual systemic exposure is negligible.